References

  1. De Chaisemartin L, Loriot MA. Pharmacogénétique des médicaments anticancéreux. Pathol Biol (Paris). 2005 Mar;53(2):116-24. PubMed | Google Scholar

  2. Ingelman-Sundberg M. Genetic and environmental causes for interindividual variability in drugs pharmacokinetics. Int Congr Ser. 2001, 1220:175-186. PubMed | Google Scholar

  3. Kalow W. Pharmacogenetics. Heredity and the response to drugs. 1962. London. Philadelphia, Saunders.

  4. Brouwer KL, Pollack GM. Pharmacogenetics: Is the right drug for the right patient sufficient? Adv Drug Deliv Rev. 2002 Nov 18;54(10):1243-4. Google Scholar

  5. Gonzalez FJ, Meyer UA. Molecular genetics of the debrisoquin-sparteine polymorphism. Clin Pharmacol Ther. 1991; 50: 233-238. PubMed | Google Scholar

  6. Buclin T, Colombo S, Biollaz J. Tests pharmacogénétiques: bientôt avant chaque prescription? Rev Med Suisse. 2008 Jul 16;4(165):1666-70. Google Scholar

  7. McDonagh EM, Whirl-Carrillo M, Garten Y, Altman RB, Klein TE. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomarkers in Medicine. 2011; 5(6):795-806. PubMed | Google Scholar

  8. Wu Alan HB. Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance. Clin Proteomics. 2011 Jul 28;8(1):12. PubMed | Google Scholar

  9. Wolf A, Burnat P, Garcia-Hejl C, Ceppa F. étude pharmacologique et pharmacogénétique de deux immunomodulateurs: l'azathioprine et la 6-mercaptopurine. Stratégie de prévention des complications. Gastroenterol Clin Biol. 2009 Mar;33(3):176-84. PubMed | Google Scholar

  10. Evans WE, Hon YY, Bomgaars L, Coutre S, Holdsworth M at al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol. 2001 Apr 15;19(8):2293-301. PubMed | Google Scholar

  11. Buclin T, Biollaz J, Diézi J. Transports rénaux de médicaments: mécanismes et potentiel d'interactions. Med Hyg. 2004; 62(2476):682-692. PubMed | Google Scholar

  12. Oshiro C, Mangravite L, Klein T, Altman R. PharmGKB very important pharmacogene: SLCO1B1. Pharmacogenet Genomics. 2010; 20(3): 211-216. PubMed | Google Scholar

  13. Moreau C, Siguret V, Loriot M-A. The pharmacogenetics of vitamin K antagonists: still a matter for discussion. Rev Med Interne. 2010 May;31(5):361-8. PubMed | Google Scholar

  14. Siguret V. Antivitamines K et pharmacogénétique: vers une meilleure compréhension de la variabilité individuelle de l'effet dose-réponse. Pathol Biol. 2007 ; 55(6):295-298. PubMed | Google Scholar

  15. Pirmohamed M, James S, Meakin S, Green C et al. Adverse drug reactions as a cause for admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004 Jul 3;329(7456):15-9. PubMed | Google Scholar

  16. Davies E, Green C, Mottram D, Rowe P, Pirmohamed M. Emergency re-admissions to hospital due to adverse drug reactions within 1 year of the index admission. Br J Clin Pharmacol. 2010 Nov;70(5):749-55. PubMed | Google Scholar

  17. B Jefferys David, Leakey Diane, Lewis John et al. New active substances authorized in the United Kingdom between 1972 and 1994. Br J Clin Pharmacol. 1998 Feb;45(2):151-6. PubMed | Google Scholar

  18. Davies E, Green C, Taylor S, Williamson P, Mottram D, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient episodes. PLoS One. 2009;4(2):e4439. PubMed | Google Scholar

  19. Sim S, Ingelman-Sundberg M. Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends Pharmacol Sci. 2011 Feb;32(2):72-81. PubMed | Google Scholar

  20. Bouayad Z, Chevalier B, Maurin R, Bartal M. Acetylation phenotype of isoniazid in Morocco. Preliminary study of 100 cases. Rev Fr Mal Respir. 1982; 10(6):401-407. PubMed | Google Scholar

  21. Elmachad M, Elkabbaj D, Elkerch F, Laarabi FZ et al. Frequencies of CYP3A5*1/*3 variants in a Moroccan population and effect on tacrolimus daily dose requirements in renal transplant patients. Genet Test Mol Biomarkers. 2012 Jun;16(6):644-7. PubMed | Google Scholar

  22. Smires FZ, Assaidi A, Loriot M-A, Moreau C et al. Effect of different genetic variants (2C9*2, 2C9*3 of cytochrome P 450 CYP2C9 and -1639G>A of the VKORC1 gene) on acenocoumarol requirement in Moroccan patients. Pathol Biol (Paris). 2012 Nov 29. pii: S0369-8114(12)00183-6. PubMed | Google Scholar